Targeting Neurodegeneration to Prevent Post-traumatic Epilepsy
Overview
Authors
Affiliations
In the quest for developing new therapeutic targets for post-traumatic epilepsies (PTE), identifying mechanisms relevant to development and progression of disease is critical. A growing body of literature suggests involvement of neurodegenerative mechanisms in the pathophysiology of acquired epilepsies, including following traumatic brain injury (TBI). In this review, we discuss the potential of some of these mechanisms to be targets for the development of a therapy against PTE.
Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures.
Rodriguez S, Sharma S, Tiarks G, Peterson Z, Jackson K, Thedens D Sci Rep. 2024; 14(1):13507.
PMID: 38867062 PMC: 11169394. DOI: 10.1038/s41598-024-63942-8.
Posttraumatic Epilepsy and Dementia Risk.
Schneider A, Law C, Gottesman R, Krauss G, Huang J, Kucharska-Newton A JAMA Neurol. 2024; .
PMID: 38407883 PMC: 10897826. DOI: 10.1001/jamaneurol.2024.0010.
Levetiracetam Pharmacokinetics and Brain Uptake in a Lateral Fluid Percussion Injury Rat Model.
Coles L, Saletti P, Lisgaras C, Casillas-Espinosa P, Liu W, Li Q J Pharmacol Exp Ther. 2023; 386(2):259-265.
PMID: 37316328 PMC: 10353071. DOI: 10.1124/jpet.122.001377.
Saletti P, Casillas-Espinosa P, Lisgaras C, Bi Mowrey W, Li Q, Liu W J Neurotrauma. 2023; 41(1-2):222-243.
PMID: 36950806 PMC: 11079442. DOI: 10.1089/neu.2022.0219.
Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms.
Hwang K, Vaknalli R, Addo-Osafo K, Vicente M, Vossel K Front Aging Neurosci. 2022; 14:903973.
PMID: 35923547 PMC: 9340804. DOI: 10.3389/fnagi.2022.903973.